The U.S. Food and Drug Administration defines the four separate components of Female Sexual Dysfunction (FSD) to be decreased sexual desire, decreased sexual arousal, dyspareunia (pain with intercourse), and persistent difficulty in achieving or inability to achieve orgasm (anorgasmia). To establish a diagnosis of FSD, these components must be associated with personal distress, as determined by the affected woman. A topical combination of menthol/L-arginine and the specific 5-PDE inhibitor vardenafil can be used to treat any of the defined components, or a combination of two or more of the defined components of FSD, as a safe, first-line therapy for FSD.